share_log

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Mar 13 21:08
Summary by Futu AI
SciSparc Ltd., a foreign private issuer, reported on March 12, 2024, that its collaborative venture MitoCareX Bio Ltd. has made significant progress in the development of cancer therapeutics. MitoCareX, working with Dr. Alon Silberman, has virtually screened millions of small molecules using a computational drug discovery platform, identifying several with potential anti-cancer properties. These findings were validated through in-vitro screening systems targeting the mitochondrial SLC25 protein family. Furthermore, MitoCareX is advancing towards the creation of a predictive AI model to enhance the efficiency of navigating chemical spaces and discovering novel anti-cancer scaffolds. The report includes forward-looking statements and is incorporated by reference into the company's registration statements filed with the SEC. SciSparc's CEO and CFO, Oz Adler, signed the report on March 13, 2024.
SciSparc Ltd., a foreign private issuer, reported on March 12, 2024, that its collaborative venture MitoCareX Bio Ltd. has made significant progress in the development of cancer therapeutics. MitoCareX, working with Dr. Alon Silberman, has virtually screened millions of small molecules using a computational drug discovery platform, identifying several with potential anti-cancer properties. These findings were validated through in-vitro screening systems targeting the mitochondrial SLC25 protein family. Furthermore, MitoCareX is advancing towards the creation of a predictive AI model to enhance the efficiency of navigating chemical spaces and discovering novel anti-cancer scaffolds. The report includes forward-looking statements and is incorporated by reference into the company's registration statements filed with the SEC. SciSparc's CEO and CFO, Oz Adler, signed the report on March 13, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.